| [1] |
Slamon DJ, Goldolphin W, Jones LA, et al. Studies of the HER-2/proto-oncogene in human breast cancer and ovarian cancer [J]. Science,1989,244(4905):707-712.
|
| [2] |
Hudis CA. Trastuzumab: mechanism of action and use in clinical practice [J]. N Engl J Med,2007,357(1):39-51.
|
| [3] |
江泽飞,邵志敏,徐兵河.人表皮生长因子受体2 阳性乳腺癌临床诊疗专家共识[J].中华肿瘤杂志,2010,32(2):158-160.
|
| [4] |
《乳腺癌HER-2 检测指南》编写组.乳腺癌HER2 检测指南[J].中华病理学杂志,2006,35,(10):631-633.
|
| [5] |
Ring A, Smith IE, Dowsett M. Circulating tumour cells in breast cancer [J]. Lancet Oncol,2004,5(2):79-88.
|
| [6] |
Gilbey AM, Burnett D, Coleman RE, et al. The detection of circulating breast cancer cells in blood [J].J Clin Pathol,2004,57(9):903-911.
|
| [7] |
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J]. N Engl J Med,2004,351(8):781-791.
|
| [8] |
Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival[J]. Clin Cancer Res, 2006,12(14pt1):4218-4224.
|
| [9] |
Allard WJ, Matera J, Miller MC, et al.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J]. Clin Cancer Res,2004,10(20):6897-6904.
|
| [10] |
Ignatiadis M, Kallergi G, Ntoulia M,et al. Prognostic value of molecular detection of circulating tumor cell using a multimarker reverse transcription PCR assay for cytokeratin 19,mammaglobin A, and HER2 in early breast cancer [J]. Clin Cancer Res,2008,14(9):2593-2600.
|
| [11] |
Ghossein RA, Carusone L, Bhattacharya S. Review:polymerase chain reaction detection of micrometastase and circulating tumor cells:application to melanoma, prostate,and thyroid carcinomas [J]. Diagn Mol Pathol,1999,8(4)165-l75.
|
| [12] |
Riethdorf S,Fritsche H,Muller V,et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch System [J]. Clin Cancer Res,2007,13(3):920-928.
|
| [13] |
Fehm T, Müller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial [J]. Breast Cancer Res Treat,2010,124(2):403-412.
|
| [14] |
Pestrin M, Bessi S, Galardi F, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients [J]. Breast Cancer Res Treat,2009,118(3):523-530.
|
| [15] |
Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses [J].Proc Natl Acad Sci USA,2004,101(25):9393-9398.
|
| [16] |
Fehm T, Becker S, Duerr-Stoerzer S, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status[J]. Breast Cancer Res,2007,9(5):R74.
|
| [17] |
Lang JE, Mosalpuria K, Cristofanilli M, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer[J]. Breast Cancer Res Treat. 2009,113(3):501-507
|
| [18] |
Wülfing P,Borchard J,Buerger H,et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to Ⅲbreast cancer patients [J]. Clin Cancer Res,2006,12(6):1715-1720.
|